Alcohol Addiction - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 114 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Alcohol Addiction - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Alcohol Addiction - Pipeline Review, H2 2014', provides an overview of the Alcohol Addiction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Alcohol Addiction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Alcohol Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alcohol Addiction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Alcohol Addiction Overview 10
Therapeutics Development 11
Pipeline Products for Alcohol Addiction - Overview 11
Pipeline Products for Alcohol Addiction - Comparative Analysis 12
Alcohol Addiction - Therapeutics under Development by Companies 13
Alcohol Addiction - Therapeutics under Investigation by Universities/Institutes 15
Alcohol Addiction - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Alcohol Addiction - Products under Development by Companies 19
Alcohol Addiction - Products under Investigation by Universities/Institutes 21
Alcohol Addiction - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
Addex Therapeutics Ltd 23
Adial Pharmaceuticals, LLC 24
AstraZeneca PLC 25
Bionex Pharmaceuticals LLC 26
Curemark, LLC 27
D&A Pharma SAS 28
Eli Lilly and Company 29
Euthymics Bioscience, Inc. 30
Heptares Therapeutics Ltd. 31
Johnson & Johnson 32
Kyorin Pharmaceutical Co., Ltd. 33
Lohocla Research Corporation 34
Omeros Corporation 35
Pfizer Inc. 36
SK Biopharmaceuticals Co., Ltd. 37
Tekmira Pharmaceuticals Corp. 38
Tonix Pharmaceuticals Holding Corp. 39
VM Discovery, Inc. 40
Zynerba Pharmaceuticals, Inc. 41
Alcohol Addiction - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
(disulfiram + selegiline) - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
(topiramate + ondansetron hydrochloride) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ABT-436 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ADX-71441 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
amitifadine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Antisense Gene Therapy for Alcoholism - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
baclofen ER - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
carisbamate - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CM-1212 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Drug to Inhibit Triple Reuptake for Alcohol Dependence - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Drugs to Activate HAT for CNS Disorders - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Drugs to Inhibit Histone Deacetylase for CNS Disorders - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GET-73 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ibudilast - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
JNJ-31020028 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
JNJ-39220675 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
JNJ-5234801 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
LY-2940094 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
naltrexone - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
naltrexone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
OMS-405 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
OMS-527 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ondansetron hydrochloride - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PF-04457845 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
saracatinib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SLV-330 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecule for Central Nervous System - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecule to Antagonize Ghrelin for Alcoholism - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
sodium oxybate IR - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
TKM-ALDH2 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
VMD-2202 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Alcohol Addiction - Recent Pipeline Updates 93
Alcohol Addiction - Dormant Projects 102
Alcohol Addiction - Discontinued Products 103
Alcohol Addiction - Product Development Milestones 104
Featured News & Press Releases 104
Apr 30, 2014: ADial Pharmaceuticals Announces Issuance of First U.S. Patent 104
Nov 04, 2013: Clinical Trial Indicates Gabapentin Is Safe and Effective for Treating Alcohol Dependence 104
Oct 10, 2013: Tekmira Provides Corporate Update on TKM-ALDH2 106
Aug 25, 2013: National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova's MN-166 in Treating Alcoholism 107
Aug 12, 2013: ADial Pharmaceuticals Announces Publication of Study on AD04 for the Treatment of Patients With Alcohol Use Disorder 108
Aug 09, 2013: Curemark wins patent for CM-1212 to treat drug, alcohol addiction 108
May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 109
Apr 30, 2013: Addex Therapeutics Reports ADX71441 Reduces Alcohol Intake In Preclinical Model Of Chronic Alcohol Dependence 109
Apr 18, 2013: ADial Pharma Announces Agreement With FDA For Phase III Trial Of AD04 For Alcohol Use Disorder In Patients Of Targeted Genotypes 110
Oct 29, 2012: Addex Therapeutics Announces Positive Preclinical Data For ADX71441 For Treatment Of Alcoholism 111
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 114
Disclaimer 114

List of Tables
Number of Products under Development for Alcohol Addiction, H2 2014 11
Number of Products under Development for Alcohol Addiction - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Alcohol Addiction - Pipeline by AbbVie Inc., H2 2014 22
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H2 2014 23
Alcohol Addiction - Pipeline by Adial Pharmaceuticals, LLC, H2 2014 24
Alcohol Addiction - Pipeline by AstraZeneca PLC, H2 2014 25
Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2014 26
Alcohol Addiction - Pipeline by Curemark, LLC, H2 2014 27
Alcohol Addiction - Pipeline by D&A Pharma SAS, H2 2014 28
Alcohol Addiction - Pipeline by Eli Lilly and Company, H2 2014 29
Alcohol Addiction - Pipeline by Euthymics Bioscience, Inc., H2 2014 30
Alcohol Addiction - Pipeline by Heptares Therapeutics Ltd., H2 2014 31
Alcohol Addiction - Pipeline by Johnson & Johnson, H2 2014 32
Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 33
Alcohol Addiction - Pipeline by Lohocla Research Corporation, H2 2014 34
Alcohol Addiction - Pipeline by Omeros Corporation, H2 2014 35
Alcohol Addiction - Pipeline by Pfizer Inc., H2 2014 36
Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 37
Alcohol Addiction - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 38
Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2014 39
Alcohol Addiction - Pipeline by VM Discovery, Inc., H2 2014 40
Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2014 41
Assessment by Monotherapy Products, H2 2014 42
Assessment by Combination Products, H2 2014 43
Number of Products by Stage and Target, H2 2014 45
Number of Products by Stage and Mechanism of Action, H2 2014 47
Number of Products by Stage and Route of Administration, H2 2014 49
Number of Products by Stage and Molecule Type, H2 2014 51
Alcohol Addiction Therapeutics - Recent Pipeline Updates, H2 2014 93
Alcohol Addiction - Dormant Projects, H2 2014 102
Alcohol Addiction - Discontinued Products, H2 2014 103